ACRES and inVentiv Health Partner to Promote Operational Excellence and Shared, Global Clinical Research Platform
inVentiv Clinical Trial Recruitment Solutions and the Alliance for Clinical Research Excellence and Safety are partnering toward the development of a global system
inVentiv Clinical Trial Recruitment Solutions (iCTRS) and the Alliance for Clinical Research Excellence and Safety (ACRES) are partnering toward the development of a global system to support responsible conduct of clinical trials according to the highest standards of safety, quality and efficiency. The partnership between ACRES and inVentiv focuses on developing and adopting global standards and performance metrics as the basis for clinical research best practices and guidelines, and developing a global information platform for effective trial management. iCTRS brings expertise in global, data-driven decision support systems, advanced informatics technologies and a patient-centric approach for trial acceleration.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
